Amahitamo mato yo kuvura kanseri y'ibihaha 2026: Ibishya ADC & Immunotherapy 

Uburyo buto bwo kuvura kanseri y'ibihaha mu 2026 byahindutse ku buryo bugaragara, biva mu buryo bwa chimiotherapie gusa bijya mu buvuzi buhanitse burimo immunotherapie, conjugate ya antibody-ibiyobyabwenge (ADCs), hamwe n’abashoramari ba T-selile. Ibipimo bigezweho birimo chimiotherapie ishingiye kuri platine ihujwe na PD-L1 inhibitor kugirango yite ku murongo wa mbere, mu gihe ibintu bishya byagezweho nka DLL3 bivura bigamije kuvura hamwe na antibody ebyiri za antibody ADC zirimo gusobanura ingaruka zo kubaho ku ndwara zidakira ndetse n’icyiciro kinini.

Sobanukirwa nuburyo bugezweho bwa selile ntoya yo kuvura kanseri yibihaha

Kanseri ntoya y'ibihaha (SCLC) ikomeje kuba bumwe muburyo bukabije bwo kurwara nabi, burangwa no gukura vuba na metastasis kare. Amateka, utuntu duto two kuvura kanseri y'ibihaha byagarukiraga kuri chimiotherapie ya platine-etoposide, yatangaga ibisubizo byambere byo gusubiza ariko bikabaho igihe kirekire. Hagati yo kubaho hagati ya SCLC (ES-SCLC) ni gake cyane yarenze umwaka.

Ariko, ibibanza byo kuvura byahinduye paradigm. Kwishyira hamwe kwa immunite igenzura ibuza umurongo wa mbere protocole byahindutse urwego rushya rwisi. Byongeye kandi, 2026 ni umwaka wingenzi aho uburyo bushya, harimo na T-selile bispecificateur hamwe na ADC izakurikiraho, biva mubyiciro byubushakashatsi bikajya mubyukuri. Iterambere ryakemuye ibikenewe cyane muburyo bwa kabiri bwo kuvura no kumurongo wa gatatu, agace kamaze imyaka mirongo idahagaze.

Itondekanya rya SCLC mubice bigarukira (LS-SCLC) na Byagutse-Icyiciro (ES-SCLC) bikomeje gutegeka ingamba zambere zo kuvura. LS-SCLC irashobora gukira hamwe na chimoradiotherapi ihuriweho hamwe no gukingira immunotherapy. Ibinyuranye, ES-SCLC icungwa nkibintu byabaye karande, byibanda kuramba no gukomeza ubuzima bwiza binyuze mubuvuzi bwa sisitemu. Gusobanukirwa iri tandukaniro ningirakamaro kubarwayi n'abarezi bayobora ibintu byinshi biboneka utuntu duto two kuvura kanseri y'ibihaha.

Uruhare rwa Subtyping ya Molecular mubuvuzi bugezweho

Ubushakashatsi buherutse gukorwa bwerekanye itandukaniro rya SCLC, biganisha ku kumenyekanisha insimburangingo ya molekile ishingiye ku kwerekana ibintu by'ingenzi byandikirwa nka ASCL1, NEUROD1, POU2F3, na YAP1. Ibi byiciro ntibikiri amasomo gusa; itangiye guhindura ibishushanyo mbonera byubuvuzi hamwe nuburyo bwo kuvura bwihariye. Kurugero, insimburangingo zimwe zishobora gusubiza neza ubudahangarwa bwihariye cyangwa imiti igamije nka DLL3 inhibitor.

Mugihe isuzumabumenyi rusange kuri ubu bwoko butaramenyerewe mumavuriro yose, kumenya ubwo bwoko butandukanye bwibinyabuzima bifasha gusobanura impamvu abarwayi bamwe bitabira neza imiti yubudahangarwa mugihe abandi batabikora. Mugihe tugenda muri 2026, ibiteganijwe nuko imyirondoro ya molekile izahinduka igice gisanzwe cyibikorwa byo gusuzuma, bikarushaho kunonosora ihitamo rya utuntu duto two kuvura kanseri y'ibihaha.

Ibipimo Byambere-Umurongo: Immunotherapy Gukomatanya

Ibuye rikomeza imfuruka yubuvuzi bugezweho bwa kanseri ya kanseri y'ibihaha ntoya ni ihuriro rya chimiotherapie ishingiye kuri platine hamwe na inhibitor ya immunite. Ubu buryo bwerekanye inyungu zihoraho zo kubaho mu bigeragezo byinshi binini byo mu cyiciro cya III, bishyiraho igipimo gishya cyo kwita.

Ubu buryo bukubiyemo gukoresha chimiotherapie kugirango itere urupfu rw'uturemangingo, "twibanze" mikorobe y'ibibyimba. Wongeyeho ubudahangarwa bw'umubiri, ubusanzwe PD-L1 cyangwa PD-1 inhibitor, birinda guhagarika T-selile, bigatuma ubudahangarwa bw'umubiri bukomeza kwibasira kanseri ya kanseri. Iyi mikoranire yahinduye prognoz kubarwayi benshi.

• Atezolizumab: Ukurikije igeragezwa rya IMpower133, atezolizumab ifatanije na karboplatine na etoposide niyo gahunda yambere yerekanye inyungu zikomeye zo kubaho muri rusange. Ikurikiranwa ryigihe kirekire ryatanzwe muri 2026 ryemeza umurizo uramba, hamwe nabarwayi barokotse imyaka itanu.
• Durvalumab: Ikigeragezo CASPIAN yashyizeho durvalumab wongeyeho platine-etoposide nkubundi buryo bukomeye. Amakuru agezweho yerekana umwirondoro wumutekano mwiza kandi uhindagurika muguteganya, bigatuma uhitamo muri sisitemu nyinshi zubuzima.
• Serplulimab: Amakuru agaragara yerekana ko serplulimab, igitabo gishya cya PD-1 inhibitor, itanga imbaraga zikomeye. Ubushakashatsi bwatanzwe mu nama nkuru ya onkologiya mu 2026 bwerekana ibisubizo bitanga umusaruro iyo bikoreshejwe hamwe na chimiotherapie, cyane cyane mu mibare y’abarwayi.
• Adebrelimab: Ubu bushya bwo murugo bwerekanye ibisubizo bitangaje mubushakashatsi bunini. Ubushakashatsi bwa CAPSTONE-1 bumaze igihe kirekire bugaragaza iterambere ryinshi mubuzima bwo hagati muri rusange, bishimangira agaciro k'imiti itandukanye ikingira indwara muri arsenal yo kuvura.

Ubuvuzi bwo guhuriza hamwe indwara zidasanzwe

Ku barwayi bafite uburwayi buke, intego yo kuvura irakiza. Ibipimo byubuvuzi bikubiyemo imiti ya chimoradiotherapi (cCRT). Intambwe ikomeye mumyaka yashize ni iyemezwa ryo gukingira immunotherapy nyuma ya cCRT.

Ikigeragezo cya ADRIATIC cyabaye umukino uhindura umukino muriyi miterere. Yerekanye ko gutanga durvalumab nkumuti wo guhuriza hamwe nyuma ya cCRT igenda neza byongerera ubuzima ubuzima butagira amajyambere no kubaho muri rusange. Ubu bushakashatsi bwatumye habaho kwemeza no kuvugurura umurongo ngenderwaho, bituma immunotherapy ikomatanyirizwa hamwe ari itegeko ku barwayi ba LS-SCLC bujuje ibisabwa.

Byongeye kandi, iperereza kuri hypofractionated radiotherapy gahunda hamwe na immunotherapie birakomeje. Ibisubizo byambere byerekana ko guhindura imishwarara yimishwarara bishobora kongera ubudahangarwa bw'umubiri, bishobora kuzamura umusaruro. Izi ngamba zihindagurika zerekana guca inyuma utuntu duto two kuvura kanseri y'ibihaha ku ndwara zaho.

Kwiyongera kwa Antibody-Ibiyobyabwenge (ADCs)

Antibody-Ibiyobyabwenge (ADCs) byerekana itsinda ryimpinduramatwara ya utuntu duto two kuvura kanseri y'ibihaha. Bitandukanye na chimiotherapie gakondo, ifata ingirabuzimafatizo zose zigabanya vuba, ADC ikora nka "misile ziyobowe." Zigizwe na antibody yibasira proteine ​​yihariye hejuru ya kanseri ya kanseri, ifitanye isano na cytotoxic ikomeye. Iyo antibody imaze guhuza intego, uruganda ruba rwinjiye imbere, kandi umutwaro urekurwa neza imbere muri selile yibibyimba, bikagabanya kwangirika kwinyama nzima.

Mu 2026, ADC zirimo gukurura abantu gusa nk'ubuvuzi bwa kabiri gusa ariko kandi bufatanije na immunotherapie yo kuvura umurongo wa mbere. Ubu buryo bubiri bukoresha neza neza ADC n'imbaraga za sisitemu yo gukingira indwara.

B7-H3 Intego ADCs: Ifinatamab Deruxtecan

Kimwe mu bintu bishimishije cyane ni ukugaragara kwa B7-H3 yibasiwe na ADC, nka ifinatamab deruxtecan (I-DXd). B7-H3 ni poroteyine igaragara cyane kuri selile ya SCLC ariko igarukira mubice bisanzwe, bigatuma iba intego nziza.

Amavuriro yatanzwe vuba aha yerekana amasezerano adasanzwe. Mu barwayi bafite ibyiciro byinshi bya SCLC bari barateye imbere nyuma yubuvuzi bwambere, I-DXd yerekanye igipimo cyibisubizo kirenze 50% naho igipimo cyo kurwanya indwara kirenga 90%. Birashoboka cyane cyane kunenga, iyi agent yerekanye ubushobozi bwo kurenga inzitizi yubwonko bwamaraso.

Ubwonko bwubwonko nibisanzwe kandi byangiza SCLC. Ubuvuzi gakondo bukunze kunanirwa kwinjira muri sisitemu yo hagati. Ubushobozi bwa I-DXd bwo kugabanya ibibyimba byo mu nda bitanga umurongo w'ubuzima ku barwayi bari bafite amahitamo make cyane. Ibigeragezo bikomeje icyiciro cya III biragereranya iyi miti na chimiotherapie isanzwe, hamwe nibisubizo biteganijwe ko byongera gusobanura umurongo wa kabiri wubuvuzi.

Intego ebyiri-Intego ADCs: Iza-bren (BL-B01D1)

Undi mipaka ni iterambere rya ADCs bispecific. Iza-bren (BL-B01D1) niyambere-mu cyiciro cya EGFR × HER3 ebyiri-yibasiye ADC. Mugihe EGFR na HER3 bikunze kuba bifitanye isano na kanseri yibihaha itari ntoya, imvugo yabo muri SCLC hamwe nuburyo budasanzwe bwibi biyobyabwenge byatanze ibisubizo bitangaje.

Ubushakashatsi bwa Phase II buherutse guhuza iza-bren na serplulimab bwerekanye ibipimo byo kubaho bitigeze bibaho. Imibare yerekana umwaka umwe muri rusange igipimo cyo kubaho kigera kuri 86%, iyi mibare iruta cyane ibipimo ngenderwaho byamateka yindwara zo mu byiciro byinshi. Ubu buryo busa nkaho butarimo kwica selile gusa ahubwo no guhindura ibibyimba "bikonje" (bidakingira immunologique) mubyimba "bishyushye", bityo bikazamura imikorere yubudahangarwa hamwe.

Izi ngaruka zoguhuza zigaragaza icyerekezo cyingenzi muri 2026: kwimuka muburyo bwo kuvura bufatika. Muguhuza ADC itera urupfu rw'uturemangingo hamwe na inhibitor igenzura feri kuri sisitemu yubudahangarwa, abaganga bagera kubisubizo byimbitse kandi biramba. Udushya twagutse kuri horizon ya viable utuntu duto two kuvura kanseri y'ibihaha.

Intego DLL3: Igihe gishya cyubuvuzi bwuzuye

Ligand 3 isa na Delta (DLL3) ni poroteyine yo hejuru iboneka kuri selile ntoya ya kanseri y'ibihaha ariko ntibiboneka mubice bisanzwe byabantu bakuru. Ibi bituma iba intego nziza yubuvuzi bwuzuye. Imyaka myinshi, kwibasira DLL3 byagaragaye ko bigoye, ariko 2026 yabonye gukura muburyo bubiri butandukanye: Bispecific T-selile Engagers (BiTEs) hamwe nubuvuzi bwa Radioligand.

Tarlatamab: Bispecific T-selile Engager

Tarlatamab ni T-selile bispecificateur ihuza umubiri T-selile yumurwayi na DLL3 yerekana kanseri. Mugukemura iki cyuho, bihatira sisitemu yumubiri gutera ikibyimba tutitaye ko T-selile zisanzwe zizi kanseri.

Kwihutisha kwemererwa no kwagura gahunda zo kwinjira byatumye tarlatamab iboneka kubarwayi bafite SCLC isubiramo cyangwa yanze. Igeragezwa rya Clinical ryerekanye igipimo cyibisubizo kiri hagati ya 40% na 55% mubantu babanje kuvurwa cyane, demokarasi ikunze kubona igipimo cyibisubizo kiri munsi ya 10% hamwe na chimiotherapie isanzwe.

Ariko, gukoresha tarlatamab bisaba gucunga neza. Gukora cyane kwa T-selile birashobora kuganisha kuri Syndrome ya Cytokine (CRS), igisubizo kibabaza. Byongeye kandi, amakuru nyayo yisi yerekanye ingaruka zihariye za pneumonite na nephritis. Abaganga b’amavuriro ubu bakoresha ingamba zo gufata ingamba hamwe nogukurikirana protocole ikaze kugirango bagabanye izo ngaruka, barebe ko inyungu nini ziyi miti zishobora kugerwaho neza.

Ubuvuzi bwa Radioligand Intego DLL3

Usibye gusezerana kwa selile, DLL3 nayo yibasiwe hakoreshejwe imiti ya radioligand. Ubu buryo bukubiyemo guhuza radiyo isotope kuri antibody cyangwa peptide ihuza DLL3. Imirasire itangwa neza mubyimba, ikarinda ingingo nzima.

Ibigeragezo byo mu cyiciro cya mbere byerekana ko ubu buryo bushobora kuba ingirakamaro cyane ku barwayi bafite indwara ziterwa na metastatike, harimo n'abafite amagufwa n'ubwonko. Ubushobozi bwo gutanga urugero rwinshi rwimirasire muburyo butarimo uburozi bwimirasire yo hanze ninyungu zikomeye. Mugihe hakiri iperereza cyane muri 2026, ibi byerekana ejo hazaza selile ntoya yo kuvura kanseri y'ibihaha ibyo birashobora guhita byinjira mubikorwa rusange.

Kugereranya Isesengura Ryimiti ivuka

Hamwe no kwinjiza ibiyobyabwenge bishya, guhitamo inzira nziza birashobora kugorana. Imbonerahamwe ikurikira igereranya urufunguzo rugaragara utuntu duto two kuvura kanseri y'ibihaha byaganiriweho, kwerekana uburyo bwabo, uko ibintu bimeze, nuburyo bwiza bwo gukoresha.

Iri gereranya rishimangira itandukaniro ryimiterere yubuvuzi. Aho bigeze habaho inzira imwe, ubu hariho inzira nyinshi zijyanye nibyiciro bitandukanye byindwara nibiranga ibinyabuzima. Guhitamo kuvura bigenda biterwa nubuvuzi bwambere, imiterere yimikorere, hamwe na biomarker yihariye.

Gucunga Ingaruka Zuruhande hamwe numwirondoro wumutekano

Nk utuntu duto two kuvura kanseri y'ibihaha gukomera cyane, gucunga ingaruka zabyo biba ngombwa kimwe. Buri cyiciro cyibiyobyabwenge cyerekana umwirondoro wuburozi bwihariye busaba gucunga neza.

Immunotherapy-Bifitanye isano nibintu bibi (irAEs)

Immune igenzura irashobora gutera uburibwe muri sisitemu iyo ari yo yose. Ibisanzwe irAEs harimo dermatitis, colitis, hepatite, na endocrinopathies nka tiroyide idakora neza. Igishimishije, amakuru amwe yerekana ko abarwayi bafite irAE yoroheje bashobora kugira ibisubizo byiza byibibyimba, byerekana imbaraga zikomeye z'umubiri.

Ubuyobozi busanzwe bukubiyemo corticosteroide no guhagarika by'agateganyo ibiyobyabwenge. Kumenya hakiri kare ni ngombwa. Abarwayi bigishijwe kwerekana ibimenyetso nkinkorora idakira, impiswi, cyangwa umunaniro ako kanya. Hamwe nogukurikirana neza, irAEs nyinshi zirahindurwa kandi ziracungwa.

ADC-Uburozi Bwihariye

ADC izana ibibazo byabo bwite. Indwara y'ibihaha (ILD) cyangwa pneumonite ni ibyago bizwi hamwe n'imitwaro imwe n'imwe, cyane cyane imiti ishingiye kuri deruxtecan. Ibizamini bisanzwe byerekana amashusho nibihaha biteganijwe mugihe cyo kuvura. Byongeye kandi, uburozi bwa hematologique nka neutropenia na trombocytopenia buramenyerewe kubera imiterere ya cytotoxic yo kwishura.

Isesemi, umunaniro, na alopecia nabyo ni kenshi ariko muri rusange birashobora gucungwa no kwitabwaho. Idirishya ryo kuvura ADCs ni rito, risaba gukosorwa neza no gukurikiranwa neza nitsinda ryabaganga.

Ubuyobozi bwa Tarlatamab na CRS

Gukoresha tarlatamab bisaba protocole yihariye kugirango ikore Syndrome ya Cytokine. Ibimenyetso bituruka ku muriro woroheje kugeza hypotension ikabije no kudakora neza kw'ingingo. Kwiyongera kwintambwe, aho dosiye yambere iri hasi kugirango tumenye buhoro buhoro sisitemu yumubiri, byagaragaye ko bifite akamaro mukugabanya ubukana bwa CRS.

Byongeye kandi, ibyago byo kurwara pneumonite na nephritis byagaragaye mubisesengura nyabyo bisaba abaganga gukurikirana neza imikorere yubuhumekero nimpyiko. Nubwo izo ngaruka zishobora kubaho, ubushobozi bwo gukira igihe kirekire mubibazo byangiritse bituma ubwo buvuzi bwongerwaho agaciro kubikoresho bya oncologue.

Intambwe zifatika kubarwayi n'abarezi

Kuyobora isi igoye yo kuvura SCLC birashobora kuba byinshi. Hano hari inzira ifatika yo gufasha abarwayi nimiryango kwishora mubikorwa nabashinzwe ubuzima utuntu duto two kuvura kanseri y'ibihaha.

• Intambwe ya 1: Emeza ibyiciro na Subtype: Menya neza ko gutunganya neza (Bike na Byagutse) byashizweho binyuze mumashusho yuzuye (CT, MRI, PET). Baza ibijyanye na subtyping ya molekuline niba ihari, kuko ishobora guhindura ibyangombwa byo kwipimisha kwa muganga.
• Intambwe ya 2: Muganire ku ngamba zo ku murongo wa mbere: Ku ndwara nini cyane, wemeze gahunda ikubiyemo chimiotherapie hiyongereyeho na immunite igenzura. Kubyiciro bigarukira, baza ikibazo cyigihe cyo guhuza immunotherapy nyuma ya chemoradiation.
• Intambwe ya 3: Shakisha Ikigeragezo cya Clinical: Urebye ubwihindurize bwihuse bwumurima, baza cyane kubyerekeye ibigeragezo birimo ADC cyangwa DLL3 igamije kuvura. Uburyo bwinshi bwo kuvura buragerwaho gusa binyuze muri izi gahunda.
• Intambwe ya 4: Gahunda yo gukurikirana: Shiraho gahunda yo gusikana buri gihe no gukora amaraso. Sobanukirwa n'ibimenyetso byingaruka zishobora gutera nka pneumonite cyangwa CRS hanyuma umenye igihe cyo kwitabaza byihutirwa.
• Intambwe ya 5: Tekereza Kwitaho: Kwinjiza ubuvuzi bwa palliative hakiri kare. Ibi ntibisobanura kureka; ahubwo, yibanda ku micungire yikimenyetso nubuzima bwiza, bushobora kwagura ubuzima iyo buhujwe no kuvura neza.

Kuba umuvugizi ubizi ni ngombwa. Imiterere ya utuntu duto two kuvura kanseri y'ibihaha irahinduka vuba kuruta ikindi gihe cyose, kandi uruhare rugaragara mu gufata ibyemezo rushobora kuganisha ku musaruro mwiza.

Icyerekezo kizaza hamwe nubushakashatsi

Umuvuduko mubushakashatsi bwa SCLC nta kimenyetso cyerekana umuvuduko. Kurenga kubuvuzi burimo gutera imbere, inzira nyinshi zitanga icyizere zirimo gushakishwa. Umwanya umwe ushimishije cyane ni uguhuza ibintu byinshi bishya, nko guhuza DLL3 igenewe BiTE na ADC, cyangwa guhuza immunomodulator eshatu zitandukanye.

Undi mipaka ni ugukoresha ubwenge bwa artile kugirango uhanure igisubizo kivura. Mugusesengura imibare nini yamakuru ya genomic na clinique, moderi ya AI irashobora guhita itanga inama nziza utuntu duto two kuvura kanseri y'ibihaha ku barwayi ku giti cyabo bafite ubusobanuro buhanitse.

Byongeye kandi, igitekerezo cyo "gukiza imikorere" kiragenda gikurura. Hamwe nabacitse ku icumu bamaze igihe kinini babikesheje ubudahangarwa bw'umubiri hamwe n’ibikorwa bigamije kugaragara, intego ni iyo kuva mu kwagura ubuzima gusa kugera ku buryo burambye, butavurwa. Ubushakashatsi ku ngamba zo kubungabunga hamwe na de-escalation protocole kubasubiza igihe kirekire birakomeje.

Inkingo zigamije antigene zihariye za SCLC nazo ziri mu iterambere ryambere. Izi nkingo zo kuvura zigamije gutoza ubudahangarwa bw'umubiri kumenya no gusenya kanseri ya kanseri ku buryo bwitondewe, bikaba bishobora gukumira ko bitazongera kubaho nyuma yo gutsinda kwa mbere.

Umwanzuro: Umuseke mushya wo kwita kuri SCLC

Umwaka wa 2026 uhagaze nkigihe cyamazi mumateka ya kanseri ntoya yibihaha. Ihinduka riva mubitekerezo bya nihilistic rijya mubyiringiro byukuri biterwa nubumenyi bukomeye hamwe nibitekerezo bishya. Kwinjiza immunotherapie mubipimo byubuvuzi byari intangiriro. Uyu munsi, kuza kwa antibody-ibiyobyabwenge nka ifinatamab deruxtecan na iza-bren, hamwe nubuvuzi bwa DLL3 bugamije kuvura nka tarlatamab, butanga amahirwe atigeze abaho.

Abarwayi basuzumwe na SCLC uyumunsi barashobora kubona uburyo bwagutse, buhanitse cyane bwa utuntu duto two kuvura kanseri y'ibihaha kuruta mbere hose. Mugihe ibibazo bikiriho, cyane cyane mugucunga uburozi no gutsinda ibiturwanya, inzira iragaragara hejuru. Ubufatanye hagati yabashakashatsi, abaganga, n’abarwayi butera impinduramatwara ihindura isuzuma rimwe ryica rikaba rishobora gucungwa, kandi rimwe na rimwe rikakira.

Mugihe tureba ejo hazaza, intumbero iguma kumuntu kugiti cye. Ubuvumbuzi bushya bwose butwegera intego nyamukuru: kurandura kanseri ntoya yibihaha. Kuri ubu, ubutumwa burasobanutse - hariho ibyiringiro, hariho amahitamo, kandi urugamba ntirurangira.